{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"25"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"71"},{"groupId":"BG009","value":"75"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"268"}],"units":"Participants"}],"groups":[{"description":"Participants received modakafusp alfa 0.001 up to 0.75 mg/kg, infusion, IV, Q1W on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by Q2W on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"BG000","title":"Part 1 (Dose Escalation) Schedule A"},{"description":"Participants received modakafusp alfa 0.20 up to 0.30 mg/kg, infusion, IV, Q2W on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation.","id":"BG001","title":"Part 1 (Dose Escalation) Schedule B"},{"description":"Participants received modakafusp alfa 0.40 up to 0.75 mg/kg, infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"BG002","title":"Part 1 (Dose Escalation) Schedule C"},{"description":"Participants received modakafusp alfa 1.5 up to 6.0 mg/kg, infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"BG003","title":"Part 1 (Dose Escalation) Schedule D"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"BG004","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"BG005","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"BG006","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"BG007","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"BG008","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"BG009","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"},{"description":"Participants received modakafusp alfa 60 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"BG010","title":"Japan Lead-in: Modakafusp Alfa 60 mg"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"BG011","title":"Japan Lead-in: Modakafusp Alfa 120 mg"},{"description":"Total of all reporting groups","id":"BG012","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.56","value":"60.3"},{"groupId":"BG001","spread":"7.00","value":"61.1"},{"groupId":"BG002","spread":"10.47","value":"60.4"},{"groupId":"BG003","spread":"10.34","value":"64.7"},{"groupId":"BG004","spread":"8.63","value":"61.9"},{"groupId":"BG005","spread":"12.58","value":"65.7"},{"groupId":"BG006","spread":"12.17","value":"64.1"},{"groupId":"BG007","spread":"7.77","value":"70.2"},{"groupId":"BG008","spread":"9.76","value":"66.2"},{"groupId":"BG009","spread":"9.61","value":"66.5"},{"groupId":"BG010","spread":"9.71","value":"66.66"},{"groupId":"BG011","spread":"11.31","value":"66.00"},{"groupId":"BG012","spread":"9.98","value":"65.46"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"34"},{"groupId":"BG009","value":"39"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"125"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"13"},{"groupId":"BG007","value":"15"},{"groupId":"BG008","value":"37"},{"groupId":"BG009","value":"36"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"143"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"10"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"24"},{"groupId":"BG007","value":"23"},{"groupId":"BG008","value":"51"},{"groupId":"BG009","value":"57"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"225"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"16"},{"groupId":"BG009","value":"15"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"33"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"9"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"23"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"10"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"34"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"20"},{"groupId":"BG007","value":"17"},{"groupId":"BG008","value":"38"},{"groupId":"BG009","value":"51"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"179"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"18"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"32"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Parts 1 and 2: The Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573.\n\nPart 3 and Japan Lead-in: The Full Analysis Set (FAS) included all enrolled participants who received at least 1 dose of study drug even if dose was incomplete."}